RxDoctor Payments Data

Robert Finkelstein, DO

Dermatology · Sarasota, FLNPI 1336178953

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $365,051 of the $421,410 with a category attached, or 86.6%. 48 manufacturers reported payments, led by AbbVie at 40.7% of the total. Among dermatology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$421,410in general payments, 2019–2025

Across 1,352 payments — averaging $311.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$171K
  • Galderma Laboratories, L.p.$61K
  • UCB, Inc.$49K
  • Sun Pharmaceutical Industries Inc.$45K
  • Lilly USA, LLC$42K
  • Novartis$19K
  • plus $34K from 42 others
$5,590in research payments, 2019–2025

Across 2 payments — averaging $2795.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$6K

What the payments were for

  • Consulting fees$3,9581%
  • Speaking & faculty fees$365,05187%
  • Travel & lodging$19,3895%
  • Food & beverage$32,2298%
  • Education$7840%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$421,410 in reported general payments places this provider in the 95th percentile of 1,147 dermatology providers in Florida.

See all dermatology providers in Florida →

Medicare billing

Part B allowed, 2024
$1,563,831
Medicare patients
1,499
Services billed
15,084

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx (2 Syringes)Secukinumab13$212,735
Humira PenAdalimumab13$86,697
Betamethasone Dipropionate43$1,817
Clobetasol Propionate24$1,390
Mycophenolate Mofetil13$1,265
Fluorouracil17$1,160
CiclopiroxCiclopirox Olamine59$1,142
Metronidazole22$1,131
Doxycycline Hyclate37$738
Ketoconazole51$730
Betamethasone Valerate21$590
Ciclopirox14$562
Triamcinolone Acetonide42$510
Gentamicin Sulfate15$450
ValacyclovirValacyclovir Hcl41$443

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisCosentyx (2 Syringes)$18,624$212,73513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,147 dermatology providers in Florida.

Other dermatology in Sarasota

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →